Emergent BioSolutions Inc.’s ruination of 15 million doses of COVID-19 vaccine at its Baltimore plant was not as unexpected as the Gaithersburg-based company would have the public believe, an investor has alleged in a potential class-action lawsuit accusing the business ...

Tagged with: COVID-19 Emergent Biosolutions johnson & johnson Securities Exchange Act securities fraud vaccine

Read More »